PORTLAND, Maine--(BUSINESS WIRE)--Covetrus™ (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the availability of Covetrus Script Assist, a new and more convenient way for veterinarians to leverage practice management system information to more proactively prescribe preventative medications for patients with past or upcoming appointments.
Covetrus Script Assist leverages machine learning and practice management records to quickly identify where gaps in medical care reside, particularly in areas like preventative medications. Once a prescription is "created," the veterinarian or delegate will have minimal steps in order to get a prescription to the client for fulfillment on their storefront.
“Veterinarians continue to face challenges balancing the on-demand needs of today’s consumer with the focus on delivering outstanding clinical care,” said Georgia Wraight, executive vice present and president, Covetrus Global Technology Solutions. “Covetrus Script Assist is a great addition to our proactive prescription management capabilities and will be instrumental in helping veterinarians drive better clinical outcomes.”
Signature features of Covetrus Script Assist include:
- Systematic prescribing of preventatives - Veterinarians can proactively prescribe preventatives for patients with past or upcoming appointments that have not purchased any product within the last 18 months.
- Reduced steps for issuing prescriptions - Once a proactive prescription has been “created” the veterinarian or delegate will have just a few steps in order to get a prescription to the client for fulfillment on their storefront.
- More informed compliance monitoring - The ability to quickly prescribe preventatives will drive practices closer to compliance and keep their patients healthy.
"Script Assist has simplified our prescribing process and improved our workflow," said Lenore Corazza, CCFP, practice manager, Lake Austin Blvd Animal Hospital. "Setting up patients with automatic renewals leads to improved medication adherence. Covetrus is helping us to better communicate and strengthen the trust and confidence our clients have in us."
All Covetrus prescription management customers have access to the Script Assist application and may opt-in to use it. For those interested in learning more about Covetrus Script Assist, visit http://bit.ly/CVETSA. Covetrus will demo Script Assist at the annual VMX Veterinary Meeting & Expo from January 18-22 at booth #1101.
Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform that connects our customers to the solutions and insights they need to work best. Our passion for the well-being of animals and those who care for them drives us to advance the world of veterinary medicine. Covetrus is headquartered in Portland, Maine, with more than 5,500 employees, serving over 100,000 customers around the globe. For more information about Covetrus visit https://www.covetrus.com/.
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties, including statements about our plans, objectives, expectations, and intentions. Such statements are subject to numerous risks and uncertainties. Factors that could adversely affect our business and prospects are set forth in our public filings with the Securities and Exchange Commission. Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise. Investors are cautioned not to place undue reliance on these forward-looking statements.